Discover our extensive collection of research-grade antibodies,
rigorously validated for in vivo applications.
Precisely identify antibody-specific signals using matched isotype controls optimised for in vivo experimentation.
BiosimilarsInvestigate biological therapeutic mechanisms with cost-effective, research-grade biosimilar antibodies.
Mar 27, 2026
In immunology and the field of cell and gene therapy (CGT), selective elimination of defined cell populations—commonly referred to as cell depletion—is a widely adopted strategy to interrogate the functional roles of specific cellular subsets and their associated molecular targets.
Feb 27, 2026
Executive SummaryThis standardized protocol provides evidence-based guidance for the intraperitoneal (IP) administration of InvivoPro Anti-Mouse PD-1 (CD279) Antibody (Clone RMP1-14, Cat. No. IV0100) in preclinical mouse models. Developed from aggregated indep
Jun 04, 2025
May 22, 2022
The InVivoPro Anti-Mouse CD4 in vivo antibody, Clone GK1.5 is a cornerstone tool in preclinical immunology research, enabling precise depletion of CD4⁺ T cells to study their role in immune responses. Developed by BioXCell, this monoclonal antibody target
May 22, 2022
The InVivoPro Anti-Mouse PD-L1 (B7-H1, CD274) in vivo antibody, Clone 10F.9G2 is a cutting-edge tool for preclinical cancer immunotherapy research, designed to block the PD-1/PD-L1 immune checkpoint pathway with high specificity and efficacy. Developed by
May 22, 2022
The InVivoPro Anti-Mouse PD-1 (CD279) in vivo antibody, Clone RMP1-14 has emerged as a pivotal tool in preclinical cancer immunotherapy research, enabling robust blockade of the PD-1/PD-L1 immune checkpoint pathway. This high-specificity monoclonal antibo
© 2021-2025 InvivoCrown Limited. All rights reserved.